Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.51 |
| ▸ | BCAT1 | P54687 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937303 | 0.89 | NHERF1 (0.57) | MEN1KMT2ANPC1RAB9APYGL | |
| SCHEMBL6398667 | 0.86 | MAPT (0.67) | FLT3DRD3MEN1KMT2APDGFRB | |
| SCHEMBL4937039 | 0.80 | BCAT1 (0.57) | MEN1KMT2ANPC1RAB9APYGL | |
| SCHEMBL19299545 | 0.80 | UBE2N (0.53) | MEN1KMT2APYGLMAPTALDH1A1 | |
| SCHEMBL6406653 | 0.79 | MEN1 (0.75) | FLT3MEN1KMT2APDGFRBNPC1 | |
| SCHEMBL20403100 | 0.78 | KMT2A (0.51) | FLT3DRD3MEN1KMT2APDGFRB | |
| SCHEMBL6404722 | 0.78 | MEN1 (0.58) | FLT3MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1609640 | 0.78 | FLT3 (0.60) | FLT3MEN1KMT2APDGFRBNPC1 | |
| SCHEMBL17149892 | 0.76 | FLT3 (0.61) | FLT3MEN1KMT2APDGFRBNPC1 | |
| SCHEMBL4935942 | 0.76 | MAPT (0.60) | FLT3MEN1KMT2APYGLBCAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PROSIDION LIMITED (GB) | 2008-08-07 | — | — | US | disclosed |
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PROSIDION LIMITED (GB) | 2008-08-07 | — | — | US | disclosed |
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PROSIDION LIMITED (GB) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PYGL, PYGM, CPT1A | FLT3 2919/4885DRD3 4444/4885MEN1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.